Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps

被引:25
作者
Zhang, Ying [1 ]
Chang, Yu-Chung E. [2 ]
Louis, John M. [4 ]
Wang, Yuan-Fang [2 ]
Harrison, Robert W. [2 ,3 ]
Weber, Irene T. [1 ,2 ]
机构
[1] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA
[2] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA
[3] Georgia State Univ, Dept Comp Sci, Atlanta, GA 30303 USA
[4] NIDDK, Chem Phys Lab, NIH, DHHS, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
RESOLUTION CRYSTAL-STRUCTURES; CLINICAL INHIBITORS; DRUG-RESISTANCE; IN-VITRO; TMC114; GENERATION; STABILITY; VARIANTS; SITES;
D O I
10.1021/cb4008875
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The molecular basis for high resistance to clinical inhibitors of HIV-1 protease (PR) was examined for the variant designated PRP51 that was selected for resistance to darunavir (DRV). High resolution crystal structures of PRP51 with the active site D25N mutation revealed a ligand-free form and an inhibitor-bound form showing a unique binding site and orientation for DRV. This inactivating mutation is known to increase the dimer dissociation constant and decrease DRV affinity of PR The PRP51-D25N dimers were in the open conformation with widely separated flaps, as reported for other highly resistant variants. PRP51-D25N dimer bound two DRV molecules and showed larger separation of 8.7 angstrom between the closest atoms of the two flaps compared with 4.4 angstrom for the ligand-free structure of this mutant. The ligand-free structure, however, lacked van der Waals contacts between Ile50 and Pro81' from the other subunit in the dimer, unlike the majority of PR structures. DRV is bound inside the active site cavity; however, the inhibitor is oriented almost perpendicular to its typical position and exhibits only 2 direct hydrogen bond and two water-mediated interactions with atoms of PRP51-D25N compared with 11 hydrogen bond interactions seen for DRV bound in the typical position in wild-type enzyme. The atypical location of DRV may provide opportunities for design of novel inhibitors targeting the open conformation of PR drug-resistant mutants.
引用
收藏
页码:1351 / 1358
页数:8
相关论文
共 34 条
  • [31] MOLREP: an automated program for molecular replacement
    Vagin, A
    Teplyakov, A
    [J]. JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1997, 30 : 1022 - 1025
  • [32] HIV-1 Protease: Structural Perspectives on Drug Resistance
    Weber, Irene T.
    Agniswamy, Johnson
    [J]. VIRUSES-BASEL, 2009, 1 (03): : 1110 - 1136
  • [33] STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASE
    WLODAWER, A
    ERICKSON, JW
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 : 543 - 585
  • [34] Novel P2 Tris-tetrahydrofuran Group in Antiviral Compound 1 (GRL-0519) Fills the S2 Binding Pocket of Selected Mutants of HIV-1 Protease
    Zhang, Hongmei
    Wang, Yuan-Fang
    Shen, Chen-Hsiang
    Agniswamy, Johnson
    Rao, Kalapala Venkateswara
    Xu, Chun-Xiao
    Ghosh, Arun K.
    Harrison, Robert W.
    Weber, Irene T.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (03) : 1074 - 1083